Dr Jane Osbourn, OBE, PhD

Prior to joining Alchemab, Jane served as VP of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored many key publications and patents and contributed to the discovery and development of a number of marketed antibody therapies including Humira and Durvalumab.

Jane is passionate about the development of the biotechnology sector and served as Chair of the Board of Directors of the UK BioIndustry Association from 2015-2019. She is a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise, previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel and is a member of the Crick Translational Advisory Group. Jane also currently chairs the Cambridge-based cell therapy company Mogrify.

In 2019 Jane was awarded an OBE in the Queen’s birthday honours for services to drug discovery, development and biotechnology, and was also awarded the 2019 Scrip Lifetime Achievement Award for contribution to the pharma industry.

Jane holds a BA in Natural Sciences (First Class: Biochemistry) from the University of Cambridge and a PhD from the John Innes Centre for Plant Science Research in Norwich.